Novolog (Pharm-Up 1966) Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Aviad Bossi
Chief executive officer
₪1.8m
Total compensation
| CEO salary percentage | 42.3% |
| CEO tenure | 1.5yrs |
| CEO ownership | n/a |
| Management average tenure | 3.9yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)
Nov 05
Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital
Jul 25I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease
May 07Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend
Apr 14Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality
Mar 24Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 09How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?
Feb 15
Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years
Jan 25How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?
Dec 29With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₪6m |
| Jun 30 2024 | n/a | n/a | -₪18m |
| Mar 31 2024 | n/a | n/a | -₪20m |
| Dec 31 2023 | ₪2m | ₪762k | -₪42m |
Compensation vs Market: Aviad's total compensation ($USD493.02K) is about average for companies of similar size in the IL market ($USD640.36K).
Compensation vs Earnings: Insufficient data to compare Aviad's compensation with company performance.
CEO
Aviad Bossi (48 yo)
1.5yrs
Tenure
₪1,802,000
Compensation
Mr. Aviad Bossi is Chief Executive Officer of Novolog (Pharm-Up 1966) Ltd from July 01, 2023.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.5yrs | ₪1.80m | no data | |
| Vice President of Information Systems | 2.1yrs | ₪1.08m | no data | |
| Chief Executive Officer of Trilog & Medicare to Home | no data | ₪2.33m | no data | |
| Chief Executive Officer of Ein Tal | no data | ₪1.25m | no data | |
| Chief Executive Officer of Mediplast Israel Ltd. | 6.9yrs | ₪1.19m | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Vice President of Business Development & Special Projects | 2yrs | no data | no data | |
| Vice President of Human Resources | less than a year | no data | no data | |
| Chief Executive Officer of Drug Distribution & Medical Device Company | 5.7yrs | no data | no data | |
| Chief Executive Officer of Target Care Services Ltd. | 5.7yrs | no data | no data | |
| Chief Executive Officer of Mediquip Ltd. | 7.3yrs | ₪2.03m | no data | |
| Chief Executive Officer of Generation Pharmaceuticals Ltd. | 13.7yrs | no data | no data |
3.9yrs
Average Tenure
52yo
Average Age
Experienced Management: NVLG's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Non-Executive Director | 2.2yrs | no data | no data | |
| Independent External Director | 7.7yrs | no data | no data | |
| Independent External Director | 7.7yrs | no data | no data | |
| Director | 8.4yrs | no data | no data | |
| Chairman of the Board | 7.1yrs | ₪293.00k | no data | |
| Director | 2.1yrs | no data | no data |
7.4yrs
Average Tenure
66yo
Average Age
Experienced Board: NVLG's board of directors are considered experienced (7.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:11 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novolog (Pharm-Up 1966) Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elena Rogovin | Chardan Capital Markets, LLC |